Developing Novel Antibiotics Consultancy
Dame Sally Davies, the Chief Medical Officer (England) said in 2013 that "Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics."
Despite the increasing need for new antibiotics, it is now widely accepted that the antibiotic market is broken and needs new incentives to promote the development of new antibiotics. New initiatives to help fix the broken market are underway in the UK, USA and the EU,
The Developing Novel Antibiotics Consultancy was started in November 2015 by Professor Richard James to provide advice to antibiotic developers and potential investors concerning alternatives to traditional small molecule, antibiotic discovery, specifically concentrating on the platform technologies;
There is growing evidence that these approaches could make a significant contribution to overcoming the problem of antimicrobial resistance. Potential investors in these technologies will require considerable assistance to help them choose the most promising technologies.
Professor James has developed a model in which a rapid, point of care technology is used to provide species identification of the bacterial pathogen, together with guidance on the most appropriate choice of therapy from conventional small molecule antibiotics, bacteriocins/endolysins, or bacteriophage therapy.
Professor James is a member of the CARB-X/ Advisory Board. He has 40 years experience through both research and teaching of antibiotics and antibiotic resistance, and bacterial infections He also has extensive experience acting as an Expert Witness in civil disputes; further information can be found here.
The Developing Novel Antibiotics Consultancy carries Professional indemnity, Public and products liability, and Employers' liability insurance.
Last updated: December 2nd 2021
See my LinkedIn posts on AMR, bacteriocins, phage therapy and COVID-19.